Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:47:35.195Z.
Calculation as of: 2026-10-06T18:47:35.195Z.
Quote observation: 2026-10-06T18:45:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66afd7ad6fe085f612ae866be6517f9e897c4fba6e73e474a8e5d595bf17d99d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$3.39B
EV/Sales Ratio
2.70x
TTM Avg
3.65x
3Y Avg
3.66x
5Y Avg
4.78x
Market Cap
$3.21B
EV/Sales Ratio
5.10x
TTM Avg
6.76x
3Y Avg
15.91x
5Y Avg
14.09x
Market Cap
$3.44B
EV/Sales Ratio
2820.63x
TTM Avg
5544.59x
3Y Avg
5544.59x
5Y Avg
2117.19x
Market Cap
$3.49B
EV/Sales Ratio
13.86x
TTM Avg
43.04x
3Y Avg
154.35x
5Y Avg
99.29x
Market Cap
$3.53B
EV/Sales Ratio
59.69x
TTM Avg
41.61x
3Y Avg
25.98x
5Y Avg
22.10x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.33B | N/A | N/A | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.32B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.38B | 6.61x | 3.21x | 2.88x | 3.18x |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 2.70x | 3.65x | 3.66x | 4.78x |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.21B | 5.10x | 6.76x | 15.91x | 14.09x |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 2820.63x | 5544.59x | 5544.59x | 2117.19x |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | 13.86x | 43.04x | 154.35x | 99.29x |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.53B | 59.69x | 41.61x | 25.98x | 22.10x |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | N/A | 419.49x | 3859.32x | 1706.09x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
